Microbot Medical Announces Completion of First Clinical Procedure at Baptist Hospital of Miami

Strategic Insights -

Baptist Hospital of Miami has completed its first clinical procedure using the LIBERTY Endovascular Robotic Surgical System, a pivotal development in the Company's clinical trial. This achievement comes on the heels of the announcement that Baptist Hospital is the second clinical site to perform a procedure, following Brigham & Women's Hospital. The principal investigator, Dr. Ripal Gandhi, MD, FSVM, FSIR, performed the clinical case, and the trial is expected to support the future submission to the FDA for commercialization. The LIBERTY Endovascular Robotic Surgical System aims to improve endovascular procedures by eliminating the need for large equipment and reducing radiation exposure.

Key Takeaways:

  • Baptist Hospital of Miami is the second clinical site to perform a clinical procedure using the LIBERTY Endovascular Robotic Surgical System, following Brigham & Women's Hospital.
  • The principal investigator, Dr. Ripal Gandhi, MD, FSVM, FSIR, performed the clinical case.
  • The trial is part of the Investigational Device Exemption for LIBERTY and is expected to support the future submission to the FDA and subsequent commercialization.
  • The LIBERTY Endovascular Robotic Surgical System has the potential to democratize endovascular interventional procedures by remote operation.
  • Microbot Medical Inc. is a clinical-stage medical device company specializing in transformational micro-robotic technologies.
  • The Company's goals include improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body.

Statistics:

  • Two clinical sites are currently performing clinical procedures using the LIBERTY Endovascular Robotic Surgical System.
  • Baptist Hospital of Miami is the second clinical site to perform a procedure, following Brigham & Women's Hospital.
  • The trial is part of the Investigational Device Exemption for LIBERTY.
  • The Company expects the trial results to support the future submission to the FDA and subsequent commercialization.

Sources:

  • Microbot Medical Inc. (NASDAQ: MBOT) press release, July 09, 2024
  • Globe Newswire: "Microbot Medical Inc. Announces Completion of First Clinical Procedure at Baptist Hospital of Miami"
  • About Microbot Medical
  • Safe Harbor Statements to future financial and/or operating results